Search clinical trials for: Gliclazide MR and Insulin Glargine Injection

Total 722 results

Servier (Tianjin) Pharmaceutical Co. LTD.

Completed

Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes (CODMS)

Type 2 Diabetes

China
LMC Diabetes & Endocrinology Ltd.

Completed

The Effect of Soliqua on Glucose Variability in Type 2 Patients Among South Asians (VARIATION 2 SA)

Diabetes Mellitus, Type 2

Canada
Sanofi

Completed

Insulin Glargine in Type 2 Diabetic Patients (TARGET)

Diabetes Mellitus, Type 2

China
Ankara University
Hacettepe University; The Scientific and Technological Research Council of...

Completed

The Effects of Insulin Detemir and Gliclazide-MR Treatments on Endothelial Functions in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Turkey
Indonesia University

Unknown

The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus

Diabetes Mellitus

Indonesia
Disphar International B.V.

Withdrawn

Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets

Comparative Bioavailability

Jordan
Gan and Lee Pharmaceuticals, USA

Completed

PK/PD Biosimilarity Study of Gan & Lee Insulin Glargine Injection vs.US & EU Lantus® in Type 1 Diabetes Mellitus Patients

Diabetes Mellitus, Type 1

Germany
King Faisal Specialist Hospital & Research Center

Completed

Glargine Insulin vs.Continuous Regular Insulin in Diabetic Surgical Patients Receiving Parenteral Nutrition (GLUCOSE-in-PN) (GLUCOSE-in-PN)

Diabetic Patients With Gastrointestinal Cancer Undergoing Surgery and Receiving Parenteral Nutrition

Saudi Arabia
Sanofi

Terminated

LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Hungary
Sanofi

Completed

Insulin Glargine [rDNA Origin] Injection vs Pioglitazone as add-on Therapy in Patients Failing Monotherapy With Sulfonylurea or Metformin

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

A Trial Comparing the Safety and Efficacy of Insulin Degludec and Insulin Glargine, Both With Insulin Aspart as Mealtime Insulin in Subjects With Type 1 Diabetes (SWITCH 1)

Diabetes | Diabetes Mellitus, Type 1

United States, Poland, Puerto Rico
Indonesia University

Completed

Immunogenicity Study of Insulin Glargine Ezelin vs Lantus in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus

Indonesia
Sanofi

Completed

Insulin Glargine in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Novo Nordisk A/S

Completed

Comparison of Biphasic Insulin Aspart 70/30 Versus Insulin Glargine in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

United States, Canada, Puerto Rico
ikfe-CRO GmbH
IKFE Institute for Clinical Research and Development

Unknown

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Insulin-requiring Type 2 Diabetes Mellitus

Germany
Merck Sharp & Dohme LLC

Terminated

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

Diabetes Mellitus, Type 2
Brigham and Women's Hospital
Sanofi

Terminated

The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Gan and Lee Pharmaceuticals, USA

Completed

Gan & Lee Insulin Glargine Target Type (1) Evaluating Research (GLITTER 1)

Diabetes Mellitus, Type 1

Spain, United States, Germany, Czechia, Hungary, Poland
Novo Nordisk A/S

Completed

Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

Diabetes Mellitus, Type 2 | Diabetes

Turkey
Gan and Lee Pharmaceuticals, USA

Completed

Gan & Lee Insulin Glargine Target Type (2) Evaluating Research (GLITTER 2)

Diabetes Mellitus, Type 2

United States
Novo Nordisk A/S

Completed

Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy (INITIATE)

Diabetes Mellitus, Type 2 | Diabetes

United States
Sanofi

Completed

Compare Blood Sugar Level Between Lantus in the Morning and Other Insulins in Type 1 Diabetes Adolescents

Diabetes Mellitus

United States
Novo Nordisk A/S

Completed

A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 5)

Diabetes Mellitus, Type 2

United States, Poland, Puerto Rico, Canada, Hungary, Germany, Turkey, Greece
Nemours Children's Clinic

Completed

Insulin Pump Therapy in Adolescents With Newly Diagnosed Type 1 Diabetes (T1D)

Diabetes Mellitus, Insulin-Dependent

United States
Guillermo Umpierrez, MD
Medical University of South Carolina; Sanofi; Texas A&M University

Completed

Basal Bolus Versus Basal Insulin in Type 2 Diabetes Mellitus (T2DM) (Basal-Plus)

Hyperglycemia | Type 2 Diabetes

United States
M.D. Anderson Cancer Center
Novo Nordisk A/S

Terminated

Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)

Lymphoma | Leukemia

United States
Sanofi

Completed

Single Dose Clamp Study To Compare Concentration/Time Profile And Metabolic Activity Profile Of 2 New Formulations Of Insulin Glargine With Lantus

Type 1 Diabetes Mellitus

Germany
Sanofi

Completed

Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients With T2DM

Diabetes Mellitus Type 2

Germany
Novo Nordisk A/S

Completed

A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine

Diabetes Mellitus, Type 2

Germany
Novo Nordisk A/S

Completed

A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus (DUAL™ VIII)

Diabetes Mellitus, Type 2 | Diabetes

United States, India, Italy, Mexico, Poland, Russian Federation, Slovakia, United Kingdom, Argentina, Norway, Turkey, Israel, Czechia, South Africa, Hungary, Brazil
Rabin Medical Center
Sanofi

Terminated

Treatment Satisfaction of Insulin Glargine Plus Insulin Apidra Compared With NPH Insulin Plus Insulin Apidra in Recently Diagnosed Type 1 Diabetes Children and Adolescents

Diabetes Type 1

Israel
University of Aarhus

Completed

Effect of NPH Insulin, Insulin Detemir and Insulin Glargine on GH-IGF-IGFBP Axis

Diabetes Mellitus, Type 1

Denmark
Universidad de Guanajuato

Completed

Insulin Schemes for Type 2 Diabetes Control

Type 2 Diabetes Mellitus

Mexico
Sanofi

Completed

Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. (DINAMO)

Diabetes Mellitus, Type 2

Brazil
IRCCS San Raffaele

Terminated

Normalization of Fasting Glucose and the Incidence of Restenosis After Peripheral Angioplasty (LIMBISCH)

Type 2 Diabetes Mellitus | Peripheral Vascular Disease

Italy
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus (EDITION JP II)

Type 2 Diabetes Mellitus

Japan
Medical University of Graz

Completed

A Trial to Investigate Efficacy and Usability of Published Best Practice to Control Glycaemia

Diabetes Mellitus, Type 2

Austria
Johns Hopkins University

Terminated

Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes

Hypoglycemia | Type 1 Diabetes

United States
Novo Nordisk A/S

Completed

Comparison of Pharmacodynamics and Pharmacokinetics of Biphasic Insulin Aspart 30 and Insulin Glargine and Insulin Glulisine Therapy in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Germany
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs

Type 2 Diabetes

China
Lannett Company, Inc.
Parexel; FARMOVS (Pty) Ltd

Completed

A Study to Demonstrate Pharmacokinetic and Pharmacodynamic Biosimilarity Between HEC-Glargine and US-Lantus® in Healthy Male Volunteers

Type 2 Diabetes Mellitus | Type 1 Diabetes Mellitus

South Africa
Sanofi

Terminated

Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction (INTENSIVE)

AMI

Canada, Brazil, United States, Argentina, Mexico
Sanofi

Completed

Single Dose Study With a New Insulin Glargine Formulation and Lantus® in Japanese Patients With Type 1 Diabetes Mellitus

Type 1 Diabetes Mellitus

Japan
Sanofi

Completed

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 1 Diabetes Mellitus (EDITION IV)

Type 1 Diabetes Mellitus

United States, Canada, Czech Republic, Denmark, Estonia, Finland, Hungary, Japan, Latvia, Netherlands, Puerto Rico, Romania, Sweden
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy and Safety of Insulin Degludec and Insulin Glargine 300 Units/mL in Subjects With Type 2 Diabetes Mellitus Inadequately Treated With Basal Insulin With or Without Oral Antidiabetic Drugs (CONCLUDE)

Diabetes Mellitus, Type 2 | Diabetes

United States, Poland, Puerto Rico, Canada, Denmark, Hungary, Serbia, Germany, Greece, Romania, Estonia, Norway
Novo Nordisk A/S

Completed

A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Russian Federation, Canada, United Kingdom, Ireland, France, South Africa, Ukraine
Novo Nordisk A/S

Completed

Comparison of NN1250 With Insulin Glargine in Subjects With Type 2 Diabetes (BEGIN™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Netherlands, Hungary, France, Bulgaria, Canada, Romania
Novo Nordisk A/S

Completed

A Trial Investigating the Concentration in the Blood of NN1250 in Children, Adolescents and Adults With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany

3

Subscribe